Donanemab injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- Eli Lilly and Company
- Medicine type
- Biologic
- Therapeutic area
- Neurology
- Indications recorded in the public source
- Treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia. Amyloid-beta pathology must be confirmed before starting treatment. This indication does not cover dementia of all severities.
- Indication source and scope
- Source date(s): 2024-12-17. Historical label; subsequent changes may not be included. Later dosing changes are not included.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Japan: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- Insurance classification
- Commercial insurance list only; not included in basic insurance
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Inclusion in the commercial insurance drug list does not imply payment by the basic medical insurance fund. Commercial insurance coverage depends on the individual policy.
- Insurance verification notes
- Exact match in the commercial insurance list; the basic insurance notice excludes payment.
Sources
- https://www.cnpharm.com/upload/resources/file/2025/03/18/170990.pdf
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=da298734646c4a4ca1b5ca612ee23fb1.pdf
- https://www.lillymedical.cn/file/raw/b994cece-084d-4d4c-a555-aabdbfe61719/多奈单抗注射液说明书.pdf
Open the interactive record, public price references and discussions